Lee-Anne Stayner

机构：University Health Network, Princess Margaret Cancer Centre · ORCID：0009-0007-1488-9970

发表论文 63 篇 · 总被引 945 次 · h-index 12

代表论文

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial) (2023 · Annals of Oncology · 被引 104)
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials (2018 · European Journal of Cancer · 被引 71)
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (2022 · Journal of Gastrointestinal Oncology · 被引 40)
First-in-class microbial ecosystem therapeutics 4 (MET4) in metastatic solid cancer patients treated with immunotherapy: MET4-IO. (2020 · Journal of Clinical Oncology · 被引 29)
Customized autoantibodies (autoAbs) profiling to predict and monitor immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICI). (2022 · Journal of Clinical Oncology · 被引 26)
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial. (2023 · Clinical Cancer Research · 被引 11)